Products - Structural heart defects | Topic | NICE

Showing 8 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 January 2026
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 December 2025
Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
25 February 2026
Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
25 February 2026
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 August 2026
Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA)
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC